T. Rowe Price Investment Management Portfolio holdings
T. Rowe Price Investment Management, Inc. (TRPIM), a division of T. Rowe Price Group established in August 2022 and headquartered in Baltimore, Maryland, is an active investment manager overseeing hundreds of billions in assets, focusing on equity and fixed-income strategies for institutional clients and sub-advisory mandates. Spun off from the parent company founded in 1937 by Thomas Rowe Price, Jr., TRPIM operates as a distinct entity with around 900 employees, emphasizing a research-driven, long-term approach rooted in fundamental analysis and disciplined risk management. Managing portfolios like large-cap growth and international equity funds, it complements T. Rowe Price’s broader offerings while targeting sophisticated investors such as pension funds and endowments with tailored, high-conviction solutions. Under the leadership of president Rob Sharps, TRPIM upholds the firm’s legacy of integrity and client focus, adapting its founder’s value-oriented philosophy to modern institutional needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
RTX Corp
RTX
|
+$762M |
| 2 |
PTC
PTC
|
+$631M |
| 3 |
Humana
HUM
|
+$400M |
| 4 |
DTE Energy
DTE
|
+$377M |
| 5 |
Exelon
EXC
|
+$376M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BKI
Black Knight, Inc. Common Stock
BKI
|
+$892M |
| 2 |
Apple
AAPL
|
+$812M |
| 3 |
Danaher
DHR
|
+$508M |
| 4 |
Microsoft
MSFT
|
+$492M |
| 5 |
Intercontinental Exchange
ICE
|
+$460M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.05% |
| 2 | Healthcare | 21.9% |
| 3 | Financials | 12% |
| 4 | Consumer Discretionary | 11.99% |
| 5 | Industrials | 11.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
376
Starbucks
SBUX
$125B
| $45.5M | 0.03% |
498,064
-1,022,617
| -67% | -$100M |
|
377
Repligen
RGEN
$9.39B
| $45M | 0.03% |
283,282
+3,514
| +1% | +$574K |
|
|
SAFE
378
Safehold
SAFE
$1.1B
| $44.8M | 0.03% |
2,518,003
| – | – |
|
379
Guardant Health
GH
$21.6B
| $44.3M | 0.03% |
1,493,100
| – | – |
|
380
Arthur J. Gallagher & Co
AJG
$64.2B
| $44.2M | 0.03% |
194,001
+5,577
| +3% | +$1.25M |
|
381
H.B. Fuller
FUL
$3.22B
| $43.9M | 0.03% |
639,792
+22,000
| +4% | +$1.55M |
|
|
CTEV
382
Claritev Corp
CTEV
$640M
| $43.7M | 0.03% |
650,408
-24,849
| -4% | -$1.84M |
|
383
Napco Security Technologies
NSSC
$1.38B
| $42.5M | 0.03% |
1,912,126
+246,996
| +15% | +$7.49M |
|
384
Option Care Health
OPCH
$3.6B
| $42.2M | 0.03% |
1,304,436
-2,864,035
| -69% | -$96.6M |
|
385
Pennant Group
PNTG
$1.35B
| $41.6M | 0.03% |
3,738,046
-253,641
| -6% | -$2.94M |
|
|
AMK
386
DELISTED
AssetMark Financial Holdings, Inc.
AMK
| $41.6M | 0.03% |
1,658,040
-330,501
| -17% | -$9.41M |
|
387
DigitalBridge
DBRG
$2.95B
| $41.5M | 0.03% |
2,357,983
-2,272,509
| -49% | -$37.5M |
|
388
Capitol Federal Financial
CFFN
$1.1B
| $41.4M | 0.03% |
8,685,585
+2,619,142
| +43% | +$15.5M |
|
|
XIFR
389
XPLR Infrastructure LP
XIFR
$1.09B
| $41.3M | 0.03% |
1,390,359
| – | – |
|
390
Prothena Corp
PRTA
$471M
| $41.2M | 0.03% |
853,479
-22,691
| -3% | -$1.35M |
|
391
Unifirst Corp
UNF
$5.21B
| $41.1M | 0.03% |
252,277
+22,592
| +10% | +$3.73M |
|
392
10x Genomics
TXG
$7.58B
| $41.1M | 0.03% |
996,665
| – | – |
|
393
Installed Building Products
IBP
$6.54B
| $40.7M | 0.03% |
325,981
+27,313
| +9% | +$3.86M |
|
394
Visteon
VC
$2.83B
| $40.4M | 0.03% |
292,390
| – | – |
|
|
CERE
395
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $39.8M | 0.03% |
1,824,387
-35,400
| -2% | -$886K |
|
396
Zentalis Pharmaceuticals
ZNTL
$304M
| $39.6M | 0.03% |
1,972,484
-26,870
| -1% | -$682K |
|
|
CNR
397
Core Natural Resources Inc
CNR
$4.62B
| $39.6M | 0.03% |
+376,994
| New | +$30.8M |
|
|
UMH
398
UMH Properties
UMH
$1.41B
| $39M | 0.03% |
2,783,908
+805,645
| +41% | +$12.4M |
|
399
Cathay General Bancorp
CATY
$4.31B
| $38.8M | 0.03% |
1,115,031
+14,016
| +1% | +$500K |
|
400
Diodes
DIOD
$4.43B
| $38.7M | 0.03% |
+491,179
| New | +$41.3M |
|
Similar funds
T. Rowe Price Investment Management's Q3 2023 Portfolio in Review
As of Q3 2023, T. Rowe Price Investment Management held 604 positions worth $141B, down 3.6% from $147B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
T. Rowe Price Investment Management's Q3 2023 filing shows 38 new, 233 increased, 256 reduced and 33 closed positions. Its largest new stake was Ulta Beauty: 509,246 shares worth $203M. The largest sale was Black Knight, Inc. Common Stock, an estimated $892M.
By sector, the portfolio is most concentrated in Technology at 22% of assets, down from 24% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Investment Management's largest Q3 2023 buy was Ulta Beauty: 509,246 shares worth $203M.
- T. Rowe Price Investment Management added most to RTX Corp in Q3 2023, an estimated $762M increase.
- T. Rowe Price Investment Management's biggest Q3 2023 reduction was Apple, cutting an estimated $812M.
- T. Rowe Price Investment Management fully exited Black Knight, Inc. Common Stock in Q3 2023, selling an estimated $892M.
- T. Rowe Price Investment Management's ten largest holdings make up 16% of its $141B portfolio in Q3 2023.
- T. Rowe Price Investment Management opened 38 new positions and closed 33 in Q3 2023.
- T. Rowe Price Investment Management's portfolio value fell 3.6% quarter-over-quarter to $141B.
Based on T. Rowe Price Investment Management's 13F filing for Q3 2023, filed 14 Nov 2023.